Monoclonal antibodies target antigens expressed by malignant cells, making them more selective than chemotherapy. Antibodies can induce the innate immune response to destroy tumor cells, or block key extracellular sites such as receptors to induce cancer cell death. In MM, target antigens include BCMA, CD20, CD38, CD40, PD-1, and VEGF.